Form 4: DarioHealth Director Leisure Receives 20,000 Restricted Shares

DarioHealth Corp. Director Lawrence B. Leisure was granted 20,000 restricted shares of common stock, vesting two years from the grant date, following a recent 20-for-1 reverse stock split.

Summary

• Lawrence B. Leisure, a Director of DarioHealth Corp. (DRIO), was granted 20,000 shares of common stock as a restricted share award.
• The transaction is scheduled for September 11, 2025, and was filed pursuant to a Rule 10b5-1(c) plan.
• The restricted share award is set to vest on the last day of the second-year anniversary after the grant date.
• Following this transaction, Mr. Leisure will directly beneficially own 20,000 shares of common stock.
• Additionally, 12,900 shares are indirectly beneficially owned by NearWater Growth, LLC.
• The reported share numbers reflect a 20-for-1 reverse stock split that was effected on August 28, 2025.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-planned restricted stock grant to a director, which is a form of compensation and generally viewed as a positive signal of alignment with shareholder interests. It does not contain unexpected positive or negative operational news.

Positives

• Director Lawrence B. Leisure received a restricted share award of 20,000 common shares, which aligns his interests with shareholders through equity ownership.

Future Outlook

The 20,000 restricted share award granted to Director Lawrence B. Leisure is scheduled to vest on the last day of the second-year anniversary following the grant date of September 11, 2025.

Industry Context

Insider transactions, such as restricted stock grants to directors, are a common practice in publicly traded companies for executive compensation and aligning management interests with shareholders. The reporting of such transactions via Form 4 is a standard regulatory requirement.

Stakeholder Impact

• Shareholders: The grant of restricted shares to a director enhances alignment between the director's financial interests and the long-term performance of the company, potentially benefiting shareholders.
• Management: The award serves as a component of long-term incentive compensation for the director, encouraging retention and performance.

Next Steps

• Vesting of the 20,000 restricted shares on the last day of the second-year anniversary after the grant date of September 11, 2025.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock grant to a director, which is a form of compensation and aligns insider interests with shareholders. It does not provide sufficient new information regarding the company's operational performance or strategic direction to warrant a change in investment recommendation based solely on this filing.

Keywords

DarioHealth, DRIO, Form 4, insider transaction, restricted stock, stock award, director compensation, reverse stock split, 10b5-1 plan